Walter S. Woltosz Sells 20,000 Shares of Simulations Plus, Inc. (NASDAQ:SLP) Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $46.71, for a total value of $934,200.00. Following the sale, the director now owns 3,540,857 shares of the company’s stock, valued at $165,393,430.47. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Simulations Plus Stock Up 1.7 %

Shares of NASDAQ SLP traded up $0.77 during trading on Tuesday, reaching $46.95. The company had a trading volume of 207,144 shares, compared to its average volume of 102,393. The company’s fifty day moving average price is $47.80 and its 200-day moving average price is $44.14. Simulations Plus, Inc. has a 12 month low of $32.69 and a 12 month high of $52.69. The stock has a market cap of $938.53 million, a P/E ratio of 86.58 and a beta of 0.72.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Wednesday, April 3rd. The technology company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.18 by $0.02. Simulations Plus had a return on equity of 7.95% and a net margin of 16.22%. The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $17.31 million. During the same quarter in the prior year, the company earned $0.20 EPS. The firm’s revenue for the quarter was up 16.2% compared to the same quarter last year. As a group, equities analysts predict that Simulations Plus, Inc. will post 0.55 earnings per share for the current year.

Simulations Plus Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, May 6th. Investors of record on Monday, April 29th were given a dividend of $0.06 per share. The ex-dividend date of this dividend was Friday, April 26th. This represents a $0.24 annualized dividend and a dividend yield of 0.51%. Simulations Plus’s payout ratio is 45.28%.

Analyst Upgrades and Downgrades

SLP has been the subject of a number of research analyst reports. Oppenheimer boosted their price target on Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 13th. William Blair started coverage on Simulations Plus in a research report on Friday. They issued an “outperform” rating on the stock. Finally, Craig Hallum upped their price target on Simulations Plus from $51.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, June 13th.

Institutional Investors Weigh In On Simulations Plus

Institutional investors and hedge funds have recently made changes to their positions in the business. EntryPoint Capital LLC purchased a new stake in shares of Simulations Plus in the first quarter worth approximately $57,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Simulations Plus during the first quarter valued at approximately $70,000. Connecticut Wealth Management LLC purchased a new stake in shares of Simulations Plus during the first quarter valued at approximately $204,000. Janney Montgomery Scott LLC purchased a new stake in shares of Simulations Plus during the first quarter valued at approximately $208,000. Finally, Canton Hathaway LLC increased its position in shares of Simulations Plus by 25.0% during the fourth quarter. Canton Hathaway LLC now owns 5,000 shares of the technology company’s stock valued at $224,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.